secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2026-01-02T23:59:59+00:00
Accession:  0001193125-26-001077
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics receives Nasdaq delisting notice for bid price non-compliance; plans hearing and reverse split vote
--------------------------------------------------------------------------------

- Nasdaq notified delisting on Dec 30, 2025, after 180-day cure period ended Dec 29 without compliance.
- Company plans to request a hearing before the Nasdaq Hearings Panel to stay delisting.
- Proxy filed Dec 29 seeking stockholder approval for reverse stock split (1-for-5 to 1-for-30).
- No assurance of extension or successful regaining of compliance with $1.00 bid price rule.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000119312526001077/0001193125-26-001077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000119312526001077/fblg-20251230.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-001077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer